Excellent flow characteristics and high filtration capacity! Syringe filter with low protein adsorption to minimize sample loss.
The "Acrodisc Sterile Syringe Filter" features a Supor membrane made of PES, making it a versatile filter syringe for sterilization with high flow rates and low protein adsorption. Gamma-ray sterilization eliminates potential contamination from residual EOG. The Acrodisc PF and Sealam Acrodisc syringe filters are equipped with a unique pre-filter that increases the processing capacity for highly viscous solutions such as serum. Available in a wide range of sizes, it can accommodate sample volumes from 10 mL to 200 mL. 【Features】 ■ Excellent flow characteristics and high filtration capacity ■ Low protein adsorption minimizes sample loss ■ Gamma-ray sterilization eliminates potential contamination from residual EOG ■ A wide range of sizes (13 mm to 37 mm) available, accommodating sample volumes from 10 mL to 200 mL ■ The Acrodisc PF and Sealam Acrodisc syringe filters include a unique pre-filter that increases processing capacity for difficult-to-filter solutions ■ Mycoplasma removal using a pore size of 0.1 μm *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
Effective filtration area ■13 mm: 1.0 cm² ■25 mm: 2.8 cm² ■32 mm: 5.8 cm² ■37 mm: 7.5 cm² *For more details, please refer to the PDF document or feel free to contact us.*
Price range
Delivery Time
Applications/Examples of results
【Application】 ■ 0.1 and 0.2 μm pore sizes are suitable for the filtration sterilization of small amounts of buffer, media, and additives. ■ Acrodisc PF and Syringe Filters from Sealam are suitable for the clarification/filtration sterilization of viscous solutions and particulate solutions. ■ For pre-filtration and particle removal, use filters with larger pore sizes. ■ Utilized for the removal of microvesicles as pre-filtration in exosome purification (0.1 µm, 0.2 µm). *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.